79815-19-3

Basic information

• Product Name: 1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester
• Synonyms: 1,2,3,4-TETRAHYDRO-ISOQUINOLINE-3-CARBOXYLIC ACID METHYL ESTER;Methyl 1,2,3,4-tetrahydro-isoquinoline-3-carboxylate, HCl
• CAS NO: 79815-19-3
• Molecular Formula: C₁₁H₁₃NO₂
• Molecular Weight: 191.23
• Mol File: 79815-19-3.mol
• Article Data: 19

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester(79815-19-3)
• EPA Substance Registry System: 1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester(79815-19-3)

Safety Data

• Hazardous Substances Data: 79815-19-3(Hazardous Substances Data)

Usage

Chemical compound

A substance with a specific molecular structure, formed by the combination of two or more elements in a fixed proportion.

Complex structure

The molecule has a complicated arrangement of atoms and bonds.

Methyl ester derivative

A compound formed by the reaction of a carboxylic acid with methanol, resulting in the formation of an ester.

Isoquinoline alkaloids

A class of naturally occurring organic compounds that contain an isoquinoline ring and have various pharmacological properties.

Potential pharmacological properties

The compound has been studied for its possible effects on biological systems and its potential use in the development of drugs.

Precursor in the synthesis of bioactive compounds

The compound can be used as a starting material in the production of other compounds with biological activity.

Drug candidates

The compound has the potential to be developed into a drug for the treatment of various diseases and conditions.

Treatment of diseases and conditions

The compound has been investigated for its potential therapeutic use, although further research is needed to fully understand its potential.

Pharmaceutical and biotechnology industries

The compound has potential applications in these industries due to its complex structure and potential pharmacological properties.

Upstream product

• 50-00-0 formaldehyd 
• 7524-50-7 methyl (2S)-2-amino-3-phenylpropanoate hydrochloride 
• 74163-81-8 L-Tic-OH 
• 63-91-2 L-phenylalanine 
• 200644-47-9 (S)-3,4-Dihydro-1H-isoquinoline-2,3-dicarboxylic acid 2-benzyl ester 3-methyl ester 
• 404848-18-6 methyl (2S)-[(1H-1,2,3-benzotriazol-1-ylmethyl)amino]-3-phenylpropanoate 
• 252008-94-9 methyl (3S)-2-(tert-butoxycarbonyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylate 
• 67-56-1 methanol 
• 79261-58-8 (S)-3,4-dihydro-1H-isoquinoline-2,3-dicarboxylic acid 2-benzyl ester 
• 115962-35-1 (3S)-2-tert-butoxycarbonyl-1,2,3,4-tetrahydroisoquinole-3-carboxylic acid 

Downstream Products

• 393837-14-4 methyl (3S)-2-[(benzylamino)carbonyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylate 
• 1036718-07-6 (3S)-N-(O-benzyl-N-Boc-L-aspartyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid methyl ester 
• 1036717-90-4 (3S)-N-(Boc-L-phenylalaninyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid methyl ester 
• 1036718-09-8 (3S)-N-(O-benzyl-N-Boc-L-glutamyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid methyl ester 
• 1092971-68-0 (3S)-N-(Boc-L-tyrosinyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid methyl-ester 
• 1219835-18-3 (3S)-N-[Boc-S-(p-methylbenzyl)-L-cysteinyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid methyl ester 

Relevant articles and documents

NITROGEN-CONTAINING COMPOUND, METHOD FOR MANUFACTURING THE SAME, AND OPTICAL FUNCTIONAL MATERIAL INCLUDING THE SAME

PROBLEM TO BE SOLVED: To provide a novel nitrogen-containing compound having luminescence property. SOLUTION: A nitrogen-containing compound represented by the following formula (I) in which RA, RB, R1, R2, R3, R4, and X are either one of the following (1) and (2). SELECTED DRAWING: None COPYRIGHT: (C)2021,JPOandINPIT

ISOQUINOLIDINOBENZODIAZEPINES

This disclosure provides novel isoquinolidinobenzodiazepines. These compounds can also be incorporated into antibody-drug conjugates.

Design and Discovery of Novel Chiral Antifungal Amides with 2-(2-Oxazolinyl)aniline as a Promising Pharmacophore

Inspired by established succinate dehydrogenase inhibitors (SDHIs), our continuing efforts toward the discovery of chiral antifungal amides turned to the optimization of their polar regions with 2-(2-oxazolinyl)aniline as a known pharmacophore. Scaffold hopping and bioactivity-guided convergent synthesis enabled the identification of promising antifungal categories. Fine tuning of the substituents and chirality furnished seven amides (1s, 1t, 2d, 2h, 2j, 3k, and 2l) as antifungal candidates, with EC50 values lower than 5 mg/L. The first investigation of chiral amides of acyclic acids as SDHIs was conducted, and compound 2d was selected as a promising candidate against Botrytis cinerea, with a preventative efficacy of up to 93.9% at 50 mg/L, which is better than that of boscalid. The different binding models between compounds with different configurations were simulated for compound 2d and its diastereoisomers. The benefits of synthetic accessibility and cost-effectiveness highlight the practical potential for compound 2d as a good alternative to known SDHI fungicides.